Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Microbiol Immunol ; 56(3): 171-82, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22211924

ABSTRACT

Because the pathogenesis of acute respiratory distress syndrome (ARDS) induced by influenza virus infection remains unknown, we can only improve on existing therapeutic interventions. To approach the subject, we investigated immunological etiology focused on cytokines and an acute lung damage factor in influenza-induced ARDS by using a PR-8 (A/H1N1)-infected mouse model. The infected mouse showed fulminant severe pneumonia with leukocyte infiltration, claudin alteration on tight junctions, and formation of hyaline membranes. In addition to interferon (IFN)-α, plenty of keratinocyte-derived chemokines (KC), macrophage inflammatory protein 2 (MIP-2), regulated on activation normal T-cell expressed and secreted (RANTES), and monocyte chemotactic protein 1 (MCP-1) were significantly released into bronchoalveolar lavage fluid (BALF) of the model. We focused on neutrophil myeloperoxidase (MPO) as a potent tissue damage factor and examined its contribution in influenza pneumonia by using mice genetically lacking in MPO. The absence of MPO reduced inflammatory damage with suppression of leakage of total BALF proteins associated with alteration of claudins in the lung. MPO(-/-) mice also suppressed viral load in the lung. The present study suggests that MPO-mediated OCl(-) generation affects claudin molecules and leads to protein leakage and viral spread as a damage factor in influenza-induced ARDS.


Subject(s)
Influenza A Virus, H1N1 Subtype/pathogenicity , Neutrophils/immunology , Orthomyxoviridae Infections/pathology , Peroxidase/metabolism , Respiratory Distress Syndrome/pathology , Animals , Cytokines/metabolism , Female , Mice , Mice, Inbred BALB C , Mice, Knockout , Peroxidase/deficiency , Pneumonia, Viral/pathology
2.
Jpn J Infect Dis ; 60(2-3): 106-12, 2007 May.
Article in English | MEDLINE | ID: mdl-17515642

ABSTRACT

The demand for rapid and simple development of a vaccine against a newly emerging infectious disease is increasing worldwide. We previously revealed that UV-inactivated severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) virions (UV-V) elicited high levels of humoral immunity and a weak Th0 response in mice immunized subcutaneously. To ensure the safety of such a whole inactivated SARS-CoV vaccine, we additionally treated the UV-V vaccine with formalin, resulting in the UV-F-V vaccine. Analysis of the immunogenicity of the UV-F-V+alum vaccine in mice revealed that it generated comparable neutralizing serum anti-SARS-CoV IgG antibody levels as the UV-V+alum vaccine. Moreover, both vaccines induced similar frequencies of anti-SARS-CoV IgG antibody-producing cells in bone marrow. Interestingly, the UV-F-V vaccine induced fewer IgG(2a) subtype antibodies and higher interleukin-4 production in vaccinated mice than did UV-V. Thus, UV-F-V imposes a Th2-type bias on the immune response, unlike UV-V. We propose here that doubly-inactivated SARS-CoV virions by UV and formalin constitute a safe vaccine that may effectively induce neutralizing antibodies in humans.


Subject(s)
Formaldehyde/pharmacology , Severe Acute Respiratory Syndrome/prevention & control , Severe acute respiratory syndrome-related coronavirus/immunology , Th2 Cells/immunology , Vaccines, Inactivated/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Female , Humans , Mice , Mice, Inbred BALB C , Ultraviolet Rays , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/adverse effects , Viral Vaccines/administration & dosage , Viral Vaccines/adverse effects
3.
Trop Med Health ; 44: 26, 2016.
Article in English | MEDLINE | ID: mdl-27579019

ABSTRACT

BACKGROUND: Previous publications suggest that nutritional supplements have anti-trypanosome activity in vitro, although apparent efficacy was not noted in vivo. This study was conducted by experimentally infecting mice with Trypanosoma brucei brucei to assess the anti-trypanosome activity of various nutritional supplements with the hope of finding possible application in the treatment of African trypanosomiasis. METHODS: Activities of nutritional supplements were screened in vitro against bloodstream forms of T. b. brucei. To evaluate selectivity, we used two mammalian cells, Jurkat cells and Vero cells. The IC50 values and selectivity index values were calculated, and supplements with promising efficacy in vitro were selected for further testing in vivo. Mice were infected intraperitoneally with 1 × 10(3) T. b. brucei. We observed parameters for disease progression such as parasitemia, red blood cell count, white blood cell count, survivability, and splenomegaly. Morphological profiles after the treatment were analyzed by scanning electron microscopy. RESULTS: Vitamin D3 showed anti-trypanosome efficacies both in vitro and in vivo. It seemed to have suppressive effects on parasitemia, and spleen weight was also significantly lower in vitamin D3-treated mice when compared to non-treated control mice. There was, however, no significant prolonged survivability of infected mice treated with vitamin D3. Among green tea extracts, polyphenon-60 and epigallocatechin gallate had suppressive effects against T. b. brucei in vitro, but in vivo efficacies were marginal. CONCLUSIONS: Treatment with nutritional supplements, vitamin D3, and polyphenon-60 seemed to have anti-trypanosome activity in vitro and protective activity to some extent in vivo, respectively, although those supplements themselves did not have curable effects. The exact mechanisms of action are not clear, but the significant efficacy in vitro suggested direct effects of supplements against African trypanosome parasites.

4.
J Antibiot (Tokyo) ; 67(3): 213-22, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24496145

ABSTRACT

Severe respiratory disease arising from influenza virus infection has a high fatality rate. Neutrophil myeloperoxidase (MPO) has been implicated in the pathogenesis of severe influenza-induced pneumonia because extracellularly released MPO mediates the production of hypochlorous acid, a potent tissue injury factor. To search for candidate anti-influenza compounds, we screened leucomycin A3 (LM-A3), spiramycin (SPM), an erythromycin derivative (EM900, in which anti-bacterial activity has been eliminated), and clarithromycin (CAM), by analyzing their ability to inhibit MPO release in neutrophils from mice and humans. When each candidate was injected into mice infected with a lethal dose of A/H1N1 influenza virus (PR-8), LM-A3 produced the highest survival rate (80.9%). We found that LM-A3 induced beneficial effects on lung pathology and viral proliferation involved in the regulatory activity of MPO release, pro-inflammatory cytokines and interferon-α production in the lung. SPM and EM900 also induced positive survival effects in the infected mice, whereas CAM did not. We further found that these compounds inhibit virus proliferation in human pneumonia epithelial A549 cells in vitro. LM-A3 showed effective action against influenza A virus infection with high anti-viral activity in human host cells, indicating the possibility that LM-A3 is a prospective lead compound for the development of a drug for human influenza. The positive survival effect induced by EM900 suggests that pharmacological architectures between anti-bacterial and anti-influenza virus activities can be dissociated in macrolide derivatives. These observations provide valuable evidence for the potential development of novel macrolide derivatives that have strong anti-viral but no anti-bacterial activity.


Subject(s)
Antiviral Agents/pharmacology , Influenza A Virus, H1N1 Subtype/drug effects , Influenza, Human/drug therapy , Josamycin/pharmacology , Animals , Cell Line, Tumor , Clarithromycin/pharmacology , Cytokines/metabolism , Disease Models, Animal , Disease Progression , Drug Design , Epithelial Cells/virology , Erythromycin/analogs & derivatives , Erythromycin/pharmacology , Female , Humans , Influenza, Human/virology , Lung/cytology , Lung/virology , Mice , Mice, Inbred BALB C , Neutrophils/drug effects , Neutrophils/metabolism , Peroxidase/drug effects , Peroxidase/metabolism , Spiramycin/pharmacology , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL